Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,289 across all filing types
Latest filing 2022-03-09 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物2021年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2021年度业绩快报公告" which translates to "2021 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2021, including revenue, profit, and other key financial metrics. The text explicitly states that the data is preliminary and unaudited, and that the final audited data will be disclosed in the company's 2021 Annual Report. The document is relatively short (1606 characters) and serves as a quick earnings update rather than a full comprehensive report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or annual financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and audit information. Therefore, the correct classification is Earnings Release (ER).
2022-03-09 Chinese
安图生物关于二级子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding its secondary subsidiary obtaining medical device registration certificates issued by the National Medical Products Administration. It details the registration certificate numbers, product names, intended uses, and related R&D investments. The document is a regulatory announcement about a product certification event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is also not a report publication announcement or certification letter. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-12-16 Chinese
安图生物关于控股子公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding its controlling subsidiary obtaining medical device registration certificates issued by the Beijing Drug Administration. It lists detailed product registration information, expected uses, and the impact on the company. There is no financial data, no discussion of financial results, no management discussion or analysis, no voting results, no legal proceedings, no capital changes, and no mention of any report publication. The document is a regulatory announcement about a business development event (obtaining regulatory approval for products). It does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. It is a regulatory announcement about a material event affecting the company. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-12-10 Chinese
招商证券关于安图生物2021年持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (on-site inspection report) by 招商证券股份有限公司 regarding 郑州安图生物工程股份有限公司's 2021 continuous supervision work. It details the inspection of company governance, internal controls, information disclosure, independence from controlling shareholders, use of raised funds, related party transactions, and operational status. It is issued by the sponsor institution as part of regulatory oversight related to a non-public stock issuance. The document is not an annual or interim financial report, nor an earnings release or audit report. It is a standalone inspection report related to regulatory compliance and internal controls, which fits the definition of an Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive content, not just an announcement or certification. Therefore, it should be classified as AR with high confidence.
2021-12-08 Chinese
安图生物关于二级子公司取得医疗器械经营许可证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (753 characters) about a subsidiary obtaining a medical device business license. It includes details about the license and its impact on the company. There is no financial data, no report attached or referenced as being published, and no mention of regulatory certifications or filings. This is a regulatory announcement about a business license approval, which does not fit into financial reports or management changes. It is best classified as a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other categories.
2021-12-06 Chinese
安图生物关于获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates from the National Medical Products Administration. It details product registration numbers, intended uses, and potential impact on the company. The document is short (850 characters) and does not contain financial statements or detailed financial data. It is an official announcement about regulatory approval rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-11-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.